Top News
Percutaneous Ablation Appropriate for Localized Renal Tumors
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
Cannabis Legalization Not Tied to Higher Health Care Utilization
AI Model Uses Serial Imaging to Predict Lung Cancer Tx Response
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Chemotherapy-Free Combo Therapy Approved for Previously Untreated CLL
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
Similar Health Care Costs in Older Patients With AML Regardless of Induction Intensity
FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Barriers to Cancer Clinical Trial Enrollment
This fact sheet discusses potential barriers to participation in cancer clinical trials. -
The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo. -
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach? -
ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
Despite its limitations, ctDNA is emerging as a potentially powerful diagnostic tool. -
Yoga and Cancer
This fact sheet reviews the use of yoga as a supportive care tool for patients with cancer. -
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
More Features
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Predictors of TKI Response in CML Remain Elusive
High-throughput analytics failed to identify reliable markers to predict TKI response in CML.
Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
Genetic variants associated with radiation-induced breast cancer include MYC-adjacent oncogene PVT1.
A Novel Method for Biomarker Discovery in Clinical Trials
A new study reveals a unique method of biomarker discovery that has the potential to be used to identify responder subpopulations in clinical trials.
